US KRAS Inhibitors Market Analysis, 2024–2034

The US KRAS Inhibitors Market Analysis Executive Summary

KRAS inhibitors target a common cancer-causing gene mutation that was long thought impossible to drug, mainly in lung and bowel cancers.

Key segments of the KRAS Inhibitors market include target (KRAS G12C, KRAS G12D and Pan-KRAS) and indication (Non-Small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer).

US KRAS Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the KRAS Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the KRAS Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for KRAS Inhibitors Market in US

The KRAS Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

• Amgen
• Bristol Myers Squibb (Mirati)
• Eli Lilly and Company
• RRevolution Medicines
• Novartis

Healthcare Policies and Regulatory Landscape for KRAS Inhibitors Market in US

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for KRAS Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

1. 1 Market Analysis

   • 1.1 Research Scope and Assumption
   • 1.2 Objective of the study
   • 1.3 Research Methodology
   • 1.4 Reason to buy the report

2. 2 Market Analysis Executive Summary

   • 2.1 Market Analysis - Industry Snapshot & key buying criteria, 2025-2034
   • 2.2 Market Size, Growth Prospects and Key findings

3. 3 Market Dynamics

   • 3.1 Market Growth Drivers Analysis
   • 3.2 Market Restraints Analysis

4. 4 Market Segmentation

   • 4.1 By Target
   • 4.2 By Indication
   • 4.3 By End User

5. 5 By Market Share

   • 5.1 Market Analysis, Insights and Forecast – By Revenue

6. 6 Competitive Landscape

   • 6.1 Major Top Market Players Products in Pipeline
   • 6.2 R&D Initiatives
   • 6.3 Notable recent Deals
   • 6.3.1 Strategic Divestments
   • 6.3.2 Mergers & Acquisitions
   • 6.3.3 Partnerships
   • 6.3.4 Joint Ventures

7. 7 Key Company Profiles

   • 7.1 Amgen
   • 7.2 Bristol Myers Squibb (Mirati)
   • 7.3 Eli Lilly and Company
   • 7.4 Revolution Medicines
   • 7.5 Novartis

8. 8 Healthcare Policies and Regulatory Landscape

   • 8.1 Policy changes and Reimbursement scenario
   • 8.2 Government Initiatives / Intervention programs

The KRAS Inhibitors market can be segmented based on various criteria, including target, indication and end user. Here's a breakdown of the market segmentation